NewsRoom Articles - Page 1249 of 1335

WednesdayFeb 15, 2017 4:00 pm

Oramed Pharmaceuticals (NASDAQ: ORMP) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Oramed Pharmaceuticals (NASDAQ: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The company completed multiple phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).…

WednesdayFeb 15, 2017 3:30 pm

Pluristem Therapeutics (NASDAQ: PSTI) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Pluristem Therapeutics (NASDAQ: PSTI) operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. It develops placenta expanded (PLX) products, including PLX-PAD cells that are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. For more information, visit the company’s website at www.pluristem.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of…

WednesdayFeb 15, 2017 3:00 pm

Oncosec Medical, Inc. (NASDAQ: ONCS) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Oncosec Medical (NASDAQ: ONCS) is a biotechnology company that designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory…

WednesdayFeb 15, 2017 2:53 pm

CytoDyn Inc. (CYDY) PRO 140 Poster Presentation at HIV Conference

Attendees at the Conference on Retroviruses and Opportunistic Infections (February 13-16) at the Washington State Convention Center in Seattle received a two-year update on CytoDyn’s PRO 140 as a single-agent maintenance therapy for HIV-1 infection. The poster presentation is from Dr. Kush Dhody, Senior Director, Clinical Operations at Amarex Clinical Research, on behalf of CytoDyn Inc. (OTCQB: CYDY). A follow-up discussion reviewing five abstracts, hosted by Karl Salzwedel of the National Institutes of Health and under the theme ‘I Want a New Drug’, is also scheduled and expected to feature a panel of distinguished participants, including CytoDyn CEO Nader Pourhassan.…

WednesdayFeb 15, 2017 2:15 pm

Soupman, Inc. (SOUP) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Soupman (OTC: SOUP) is a manufacturer and multi-channel marketer of premium soups that are offered under the “Original Soupman” brand. Together with its subsidiaries, Soupman manufactures and sells its products to grocery chains, school systems, and franchisees. Its license from Al Yeganeh, the legendary “soupman,” provides the company with access to Yeganeh's recipes, name, likeness and other intellectual properties. It also franchises Original Soupman restaurants and mobile units, as well as other high-traffic locations such as casinos, airports, theme parks and other tourist locations. Soupman has nine franchise locations, including co-branded locations. For more information, visit the company’s website at…

WednesdayFeb 15, 2017 2:15 pm

OncoCyte Corporation (NYSE: OCX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

OncoCyte (NYSE: OCX) focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancers. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. For more information, visit the company’s website at www.oncocyte.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial…

WednesdayFeb 15, 2017 1:54 pm

SeeThruEquity Report Highlights Recent ChineseInvestors.com, Inc. (CIIX) Investments

A SeeThruEquity report released in February revealed that ChineseInvestors.com, Inc. (OTCQB: CIIX), a specialized investment services company targeting primarily the Chinese-speaking population in the U.S., has made several investments in the global cannabis industry, increasing its growth potential. Still in the early stages of market penetration, the company cited significant potential in its legal cannabis initiatives. Catalysts for potential future growth include a current stake in Medicine Man Technologies, Inc. (OTCQB: MDCL), a business with cultivation, production, and dispensary operations, which has already generated proceeds from stock sales. The company’s recent achievements include completing a $5 million private placement of…

WednesdayFeb 15, 2017 1:45 pm

22nd Century (NYSE: XXII) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company's website at…

WednesdayFeb 15, 2017 1:15 pm

BioTime (NYSE: BTX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

BioTime (NYSE: BTX) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The foundation of BioTime's core therapeutic technology platform is pluripotent cells, which are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and…

WednesdayFeb 15, 2017 1:15 pm

MagneGas Corp. (NASDAQ: MNGA) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

MagneGas (NASDAQ: MNGA) is an alternative energy company that creates and produces hydrogen-based alternative fuel through the gasification of carbon-rich liquids in the United States and internationally. The company produces gas bottled in cylinders and distributes to the metalworking market as an alternative to acetylene. It offers MagneGas, a fuel that primarily comprises hydrogen; and Plasma Arc Flow refineries that produce gas. The company also sells and licenses the plasma arc technology for the processing of liquid waste. For more information, visit the company’s website at www.magnegas.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services…

Financial news and publishing for public and private companies

Contact us: 512.354.7000